Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zapaq Inc.

Division of CoMentis Inc.

Latest From Zapaq Inc.

Attack of the Killer Bs

2006 has seen an unusual number of large Series B venture rounds in biopharma compared to last year, though Series B rounds haven't been much larger on average.
BioPharmaceutical Strategy

AC Immune SA

Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.

Zapaq Inc.

The founders of Zapaq Inc. have a straightforward objective: to develop compounds that inhibit aspartic proteases. The goal is hardly surprising, given that one of the company's founders, Jordan Tang, PhD, of the Oklahoma Medical Research Foundation was the first scientist to determine the structure of an aspartic protease and explore its basic mechanisms.

Addressing Alzheimer's

Fresh insights and tools are empowering start-ups pursuing treatments for Alzheimer's disease.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CoMentis Inc.
  • Senior Management
  • James C Jenson, PhD, CEO
  • Contact Info
  • Zapaq Inc.
    Phone: (405) 488-1206
    755 Research Pkwy., Ste 427
    Oklahoma City, OK 73104